⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
KYTX News
Kyverna Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
KYTX
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com
KYTX
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com
KYTX
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026
globenewswire.com
KYTX
Kyverna Therapeutics to Participate in Upcoming March Investor Conferences
globenewswire.com
KYTX
Kyverna Therapeutics to Participate in Upcoming March Investor Conferences
globenewswire.com
KYTX
Form 8-K
sec.gov
KYTX
Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors
globenewswire.com
KYTX
Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer
globenewswire.com
KYTX
Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference
globenewswire.com
KYTX